LOWFederal Register

Government Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapy

Published Jul 2, 2026Source: Federal RegisterView original

Summary

The NCI is offering a licensing and co-development opportunity for a conserved viral peptide (CE1) used in cancer immunotherapy targeting hepatocellular carcinoma (HCC). This is a business development/technology transfer notice rather than a regulatory restriction, presenting a potential commercialization opportunity for peptide research organizations rather than a compliance burden.

AI Analysis

Key Changes

•NCI announces availability of a government-owned invention for licensing
•Seeking research co-development partners and/or licensees for CE1-based therapeutics
•Focus on hepatocellular carcinoma (HCC) prevention and treatment via cancer immunotherapy

Affected Peptides

CE1 (conserved viral peptide)

Action Required

Interested vendors or research organizations should contact the NCI Technology Transfer Center to inquire about licensing terms or co-development partnership opportunities for the CE1 peptide.

Effective Date

Jul 2, 2026

Full Document Text

The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for viral peptide (CE1)-based therapeutics for HCC prevention and treatment.

Alert created: Jul 2, 2026, 1:01 PM